Skip to main content
Erschienen in: Drug Safety 7/2007

01.07.2007 | Original Research Article

Risk of Diabetic Ketoacidosis after Exposure to Risperidone or Olanzapine

verfasst von: Krishnan Ramaswamy, Dr Chris M. Kozma, Henry Nasrallah

Erschienen in: Drug Safety | Ausgabe 7/2007

Einloggen, um Zugang zu erhalten

Abstract

Background: Atypical antipsychotics have been associated with metabolic abnormalities including impaired glucose metabolism, exacerbation of existing diabetes mellitus and new-onset type 2 diabetes. Not all atypical antipsychotic agents appear to have the same propensity to cause these complications.
Objective: To assess diabetic ketoacidosis risk in patients receiving risperidone or olanzapine.
Methods: California Medicaid data were evaluated for the presence of a diabetic ketoacidosis hospital claim (9th Edition of the International Classification of Diseases code 2501x) for patients receiving an atypical antipsychotic agent between July 1997 and September 2000. Initial prescription claims were identified for risperidone, olanzapine, clozapine, quetiapine and multiple atypical medications; however, the final analysis was restricted to risperidone and olanzapine owing to sample size challenges in the clozapine and quetiapine groups. Cases were specified if a claim occurred within 45 days after antipsychotic dispensation. Potential confounding variables and duration of antipsychotic exposure were included.
Results: Initial users of risperidone (n = 51 330; 31 diabetic ketoacidosis) and olanzapine (n = 51 302; 55 diabetic ketoacidosis) were identified between July 1997 and September 2000. The adjusted risk of diabetic ketoacidosis for olanzapine versus risperidone was 1.62 (p = 0.033). The risk of diabetic ketoacidosis was associated with a longer duration of drug exposure. A progressive and statistically significant divergence in risk was observed between the two treatment groups after the first 30 days of therapy. For risperidone patients, diabetic ketoacidosis risk stabilised after the first 90 days; for olanzapine patients, diabetic ketoacidosis risk continued to increase until 360 days (study duration). For exposures of >30 days, >90 days and >180 days, diabetic ketoacidosis risk was 1.7 (p = 0.026), 2.4 (p = 0.004) and 3.5 (p = 0.001) times greater for olanzapine than risperidone. Treatment group, age, African American race and the presence of schizophrenia or diabetes were significant predictors of diabetic ketoacidosis.
Conclusion: The risk of diabetic ketoacidosis appears to be greater for patients exposed to olanzapine compared with risperidone after adjusting for confounding factors. This risk appears to increase with longer duration of exposure to olanzapine.
Literatur
1.
Zurück zum Zitat Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001; 62 Suppl. 27: 15–26PubMed Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001; 62 Suppl. 27: 15–26PubMed
2.
Zurück zum Zitat Koller EA, Cross JT, Doraiswamy PM, et al. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003 Jun; 23: 735–44PubMedCrossRef Koller EA, Cross JT, Doraiswamy PM, et al. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003 Jun; 23: 735–44PubMedCrossRef
3.
Zurück zum Zitat Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002 Apr; 159: 561–6PubMedCrossRef Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002 Apr; 159: 561–6PubMedCrossRef
4.
Zurück zum Zitat Koller E, Schneider B, Bennett K, et al. Clozapine-associated diabetes. Am J Med 2001 Dec 15; 111(9): 716–23PubMedCrossRef Koller E, Schneider B, Bennett K, et al. Clozapine-associated diabetes. Am J Med 2001 Dec 15; 111(9): 716–23PubMedCrossRef
5.
Zurück zum Zitat Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002 Mar; 14(1): 59–64PubMed Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002 Mar; 14(1): 59–64PubMed
6.
Zurück zum Zitat Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. EurNeuropsychopharmacol 2001 Feb; 11(1): 25–32CrossRef Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. EurNeuropsychopharmacol 2001 Feb; 11(1): 25–32CrossRef
7.
Zurück zum Zitat Ananth J, Venkatesh R, Burgoyne K, et al. Atypical antipsychotic drug use and diabetes. Psychother Psychosom 2002 Sep–Oct; 71(5): 244–54PubMedCrossRef Ananth J, Venkatesh R, Burgoyne K, et al. Atypical antipsychotic drug use and diabetes. Psychother Psychosom 2002 Sep–Oct; 71(5): 244–54PubMedCrossRef
8.
Zurück zum Zitat Cohen D. Atypical antipsychotics and new onset diabetes mellitus: an overview of the literature. Pharmacopsychiatry 2004 Jan; 37: 1–11PubMed Cohen D. Atypical antipsychotics and new onset diabetes mellitus: an overview of the literature. Pharmacopsychiatry 2004 Jan; 37: 1–11PubMed
9.
Zurück zum Zitat Lean ME, Pajonk FG. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care 2003 May; 26: 1597–605PubMedCrossRef Lean ME, Pajonk FG. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care 2003 May; 26: 1597–605PubMedCrossRef
10.
Zurück zum Zitat Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000 Jun; 157: 975–81PubMedCrossRef Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000 Jun; 157: 975–81PubMedCrossRef
11.
Zurück zum Zitat Wilson DR, D’Souza L, Sarkar N, et al. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res 2003 Jan 1; 59: 1–6PubMedCrossRef Wilson DR, D’Souza L, Sarkar N, et al. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res 2003 Jan 1; 59: 1–6PubMedCrossRef
12.
Zurück zum Zitat Hagg S, Joelsson L, Mjorndal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998 Jun; 59: 294–9PubMedCrossRef Hagg S, Joelsson L, Mjorndal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998 Jun; 59: 294–9PubMedCrossRef
13.
Zurück zum Zitat Fuller MA, Shermock KM, Secic M, et al. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 2003 Aug; 23: 1037–43PubMedCrossRef Fuller MA, Shermock KM, Secic M, et al. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 2003 Aug; 23: 1037–43PubMedCrossRef
14.
Zurück zum Zitat Caro JJ, Ward A, Levinton C, et al. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 2002 Dec; 63: 1135–9PubMedCrossRef Caro JJ, Ward A, Levinton C, et al. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 2002 Dec; 63: 1135–9PubMedCrossRef
15.
Zurück zum Zitat Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002 Oct; 63: 920–30PubMedCrossRef Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002 Oct; 63: 920–30PubMedCrossRef
16.
Zurück zum Zitat Gianfrancesco F, White R, Wang RH, et al. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 2003 Aug; 23(4): 328–35PubMedCrossRef Gianfrancesco F, White R, Wang RH, et al. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 2003 Aug; 23(4): 328–35PubMedCrossRef
17.
Zurück zum Zitat Gianfrancesco F, Grogg A, Mahmoud R, et al. Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin Ther 2003 Apr; 25: 1150–71PubMedCrossRef Gianfrancesco F, Grogg A, Mahmoud R, et al. Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin Ther 2003 Apr; 25: 1150–71PubMedCrossRef
18.
Zurück zum Zitat Koller EA, Weber J, Doraiswamy PM, et al. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry 2004 Jun; 65: 857–63PubMedCrossRef Koller EA, Weber J, Doraiswamy PM, et al. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry 2004 Jun; 65: 857–63PubMedCrossRef
19.
Zurück zum Zitat Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002 Jul; 22: 841–52PubMedCrossRef Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002 Jul; 22: 841–52PubMedCrossRef
20.
Zurück zum Zitat Hedenmalm K, Hägg S, Ståhl M, et al. Glucose intolerance with atypical antipsychotics. Drug Saf 2002; 25(15): 1107–16PubMedCrossRef Hedenmalm K, Hägg S, Ståhl M, et al. Glucose intolerance with atypical antipsychotics. Drug Saf 2002; 25(15): 1107–16PubMedCrossRef
21.
Zurück zum Zitat Koro CE, Fedder DO, L’Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002 Aug 3; 325(7358): 243PubMedCrossRef Koro CE, Fedder DO, L’Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002 Aug 3; 325(7358): 243PubMedCrossRef
22.
Zurück zum Zitat Wang PS, Glynn RJ, Ganz DA, et al. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol 2002 Jun; 22(3): 236–43PubMedCrossRef Wang PS, Glynn RJ, Ganz DA, et al. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol 2002 Jun; 22(3): 236–43PubMedCrossRef
23.
Zurück zum Zitat Meyer JM, Nasralah HA, McEvoy JP, et al. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial: clinical comparisons of subgroups with and without the metabolic syndrome. Schizophr Res 2006; 80: 9–18CrossRef Meyer JM, Nasralah HA, McEvoy JP, et al. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial: clinical comparisons of subgroups with and without the metabolic syndrome. Schizophr Res 2006; 80: 9–18CrossRef
24.
Zurück zum Zitat Church CO, Stevens DL, Fugate SE. Diabetic ketoacidosis associated with aripiprazole. Diabet Med 2005 Oct; 22: 1440–3PubMedCrossRef Church CO, Stevens DL, Fugate SE. Diabetic ketoacidosis associated with aripiprazole. Diabet Med 2005 Oct; 22: 1440–3PubMedCrossRef
25.
Zurück zum Zitat Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004 Sep; 161: 1709–11PubMedCrossRef Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004 Sep; 161: 1709–11PubMedCrossRef
26.
Zurück zum Zitat Muench J, Carey M. Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature. J Am Board Fam Pract 2001; 14: 278–82PubMed Muench J, Carey M. Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature. J Am Board Fam Pract 2001; 14: 278–82PubMed
27.
Zurück zum Zitat Citrome L, Jaffe A, Levie J, et al. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatric Services 2004; 55: 1006–13PubMedCrossRef Citrome L, Jaffe A, Levie J, et al. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatric Services 2004; 55: 1006–13PubMedCrossRef
28.
Zurück zum Zitat Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. Wiley Series in Probability and Statistics. New York, NY: John Wiley & Sons, Inc., 2000 Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. Wiley Series in Probability and Statistics. New York, NY: John Wiley & Sons, Inc., 2000
29.
Zurück zum Zitat Allison PD. Logistic Regression using the SAS system: theory and application. Cary, NC: SAS Institute Inc., 1999 Allison PD. Logistic Regression using the SAS system: theory and application. Cary, NC: SAS Institute Inc., 1999
30.
Zurück zum Zitat Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999 Sep; 156: 1417–20PubMed Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999 Sep; 156: 1417–20PubMed
31.
Zurück zum Zitat Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med 2006; 144: 350–7PubMed Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med 2006; 144: 350–7PubMed
32.
Zurück zum Zitat Subramaniam M, Chong SA, Pek E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 2003 Jun; 48(5): 345–7PubMed Subramaniam M, Chong SA, Pek E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 2003 Jun; 48(5): 345–7PubMed
33.
Zurück zum Zitat Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996 Jan–Feb; 37: 68–73PubMedCrossRef Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996 Jan–Feb; 37: 68–73PubMedCrossRef
34.
Zurück zum Zitat Regenold WT, Thapar RK, Marano C, et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002 Jun; 70(1): 19–26PubMedCrossRef Regenold WT, Thapar RK, Marano C, et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002 Jun; 70(1): 19–26PubMedCrossRef
35.
Zurück zum Zitat Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000; 26(4): 903–12PubMedCrossRef Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000; 26(4): 903–12PubMedCrossRef
36.
Zurück zum Zitat Buse JB, Cavazzoni P, Hornbuckle K, et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 2003 Feb; 56: 164–70PubMedCrossRef Buse JB, Cavazzoni P, Hornbuckle K, et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 2003 Feb; 56: 164–70PubMedCrossRef
37.
Zurück zum Zitat Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004; 65 Suppl. 7: 4–18PubMed Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004; 65 Suppl. 7: 4–18PubMed
38.
Zurück zum Zitat Ried LD, Renner BT, Bengtson MA, et al. Weight change after an atypical antipsychotic switch. Ann Pharmacother 2003 Oct; 37: 1381–6PubMedCrossRef Ried LD, Renner BT, Bengtson MA, et al. Weight change after an atypical antipsychotic switch. Ann Pharmacother 2003 Oct; 37: 1381–6PubMedCrossRef
39.
Zurück zum Zitat Wetterling T. Bodyweight gain with atypical antipsychotics: a comparative review. Drug Saf 2001 Jan; 24: 59–73PubMedCrossRef Wetterling T. Bodyweight gain with atypical antipsychotics: a comparative review. Drug Saf 2001 Jan; 24: 59–73PubMedCrossRef
40.
Zurück zum Zitat Atmaca M, Kuloglu M, Tezcan E, et al. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003 May; 64: 598–604PubMedCrossRef Atmaca M, Kuloglu M, Tezcan E, et al. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003 May; 64: 598–604PubMedCrossRef
Metadaten
Titel
Risk of Diabetic Ketoacidosis after Exposure to Risperidone or Olanzapine
verfasst von
Krishnan Ramaswamy
Dr Chris M. Kozma
Henry Nasrallah
Publikationsdatum
01.07.2007
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 7/2007
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200730070-00004

Weitere Artikel der Ausgabe 7/2007

Drug Safety 7/2007 Zur Ausgabe

Conference Paper

Signal Detection